TY - JOUR
T1 - Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy
AU - Gironda, Daniel J.
AU - Adams, Daniel L.
AU - He, Jianzhong
AU - Xu, Ting
AU - Gao, Hui
AU - Qiao, Yawei
AU - Komaki, Ritsuko
AU - Reuben, James M.
AU - Liao, Zhongxing
AU - Blum-Murphy, Mariela
AU - Hofstetter, Wayne L.
AU - Tang, Cha Mei
AU - Lin, Steven H.
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Background: Cancer Associated Macrophage-Like cells (CAMLs) are polynucleated circulating stromal cells found in the bloodstream of numerous solid-tumor malignancies. Variations within CAML size have been associated with poorer progression free survival (PFS) and overall survival (OS) in a variety of cancers; however, no study has evaluated their clinical significance in esophageal cancer (EC). Methods: To examine this significance, we ran a 2 year prospective pilot study consisting of newly diagnosed stage I-III EC patients (n = 32) receiving chemoradiotherapy (CRT). CAML sizes were sequentially monitored prior to CRT (BL), ~ 2 weeks into treatment (T1), and at the first available sample after the completion of CRT (T2). Results: We found CAMLs in 88% (n = 28/32) of all patient samples throughout the trial, with a sensitivity of 76% (n = 22/29) in pre-treatment screening samples. Improved 2 year PFS and OS was found in patients with CAMLs < 50 μm by the completion of CRT over patients with CAMLs ≥ 50 μm; PFS (HR = 12.0, 95% CI = 2.7–54.1, p = 0.004) and OS (HR = 9.0, 95%CI = 1.9–43.5, p = 0.019). Conclusions: Tracking CAML sizes throughout CRT as a minimally invasive biomarker may serve as a prognostic tool in mapping EC progression, and further studies are warranted to determine if presence of these cells prior to treatment suggest diagnostic value for at-risk populations.
AB - Background: Cancer Associated Macrophage-Like cells (CAMLs) are polynucleated circulating stromal cells found in the bloodstream of numerous solid-tumor malignancies. Variations within CAML size have been associated with poorer progression free survival (PFS) and overall survival (OS) in a variety of cancers; however, no study has evaluated their clinical significance in esophageal cancer (EC). Methods: To examine this significance, we ran a 2 year prospective pilot study consisting of newly diagnosed stage I-III EC patients (n = 32) receiving chemoradiotherapy (CRT). CAML sizes were sequentially monitored prior to CRT (BL), ~ 2 weeks into treatment (T1), and at the first available sample after the completion of CRT (T2). Results: We found CAMLs in 88% (n = 28/32) of all patient samples throughout the trial, with a sensitivity of 76% (n = 22/29) in pre-treatment screening samples. Improved 2 year PFS and OS was found in patients with CAMLs < 50 μm by the completion of CRT over patients with CAMLs ≥ 50 μm; PFS (HR = 12.0, 95% CI = 2.7–54.1, p = 0.004) and OS (HR = 9.0, 95%CI = 1.9–43.5, p = 0.019). Conclusions: Tracking CAML sizes throughout CRT as a minimally invasive biomarker may serve as a prognostic tool in mapping EC progression, and further studies are warranted to determine if presence of these cells prior to treatment suggest diagnostic value for at-risk populations.
KW - Biomarker
KW - Cancer associated macrophage-like cell
KW - Esophageal cancer
KW - Prognostic
UR - http://www.scopus.com/inward/record.url?scp=85094975808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85094975808&partnerID=8YFLogxK
U2 - 10.1186/s12967-020-02563-x
DO - 10.1186/s12967-020-02563-x
M3 - Article
C2 - 33148307
AN - SCOPUS:85094975808
SN - 1479-5876
VL - 18
JO - Journal of translational medicine
JF - Journal of translational medicine
IS - 1
M1 - 413
ER -